LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

NVO

65.43

-3.4%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

NVO

65.43

-3.4%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

NVO

65.43

-3.4%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

NVO

65.43

-3.4%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

NVO

65.43

-3.4%↓

Search

Roivant Sciences Ltd

Gesloten

SectorGezondheidszorg

10.77 -1.82

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

10.7

Max

10.99

Belangrijke statistieken

By Trading Economics

Inkomsten

212M

25M

Verkoop

4.5M

9M

EPS

-0.199

Winstmarge

280.018

Werknemers

908

EBITDA

-52M

-274M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+63.79% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

7.8B

Vorige openingsprijs

12.59

Vorige sluitingsprijs

10.77

Nieuwssentiment

By Acuity

50%

50%

209 / 382 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

Roivant Sciences Ltd Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

13 mei 2025, 23:20 UTC

Winsten

Aristocrat Leisure Boosts Half-Year Dividend, Keeps Focus on M&A

13 mei 2025, 23:48 UTC

Marktinformatie

Gold Edges Higher, Supported by Signs of Mild U.S. Inflation -- Market Talk

13 mei 2025, 23:43 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

13 mei 2025, 23:43 UTC

Marktinformatie

Nikkei May Rise on Hopes for Improving U.S.-China Trade Relations -- Market Talk

13 mei 2025, 23:24 UTC

Marktinformatie
Winsten

Global Equities Roundup: Market Talk

13 mei 2025, 23:24 UTC

Marktinformatie
Winsten

Aristocrat's 1H Result Falls Short, Jefferies Says -- Market Talk

13 mei 2025, 22:58 UTC

Winsten

Table: Samsung Fire & Marine 1Q Consolidated Net KRW609.03B Vs KRW701.95B

13 mei 2025, 22:58 UTC

Winsten

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Net KRW609.03B Vs KRW701.95B

13 mei 2025, 22:58 UTC

Winsten

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Op Pft KRW792.36B Vs Op KRW897.06B

13 mei 2025, 22:58 UTC

Winsten

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Rev KRW6.106T Vs KRW5.507T

13 mei 2025, 22:38 UTC

Winsten

Aristocrat: Continues to Actively Pursue Strategic M&A Activities

13 mei 2025, 22:38 UTC

Winsten

Aristocrat: Remains Committed to Capital Management Strategy, Ongoing Share Buy-Back Program

13 mei 2025, 22:37 UTC

Winsten

Aristocrat: Expects More Operating Momentum in 2H Amid Product Rollout, Technology Initiatives

13 mei 2025, 22:36 UTC

Winsten

Aristocrat: Sees Accelerating Performance at Interactive Unit Toward FY 2029 US$1 Bln Revenue Target

13 mei 2025, 22:35 UTC

Winsten

Aristocrat: Expects Continued Market Share Gains from Gaming Unit

13 mei 2025, 22:34 UTC

Winsten

Aristocrat: Expects to Deliver NPATA Growth Over the Full Year on a Constant Currency Basis

13 mei 2025, 22:33 UTC

Winsten

Aristocrat: Interactive Business Delivered Strong Revenue Growth

13 mei 2025, 22:33 UTC

Winsten

Aristocrat: Gaming Unit Continued to Deliver Market Share Gains

13 mei 2025, 22:33 UTC

Winsten

Aristocrat: Product Madness' Key Social Casino Franchises Continued to Outperform

13 mei 2025, 22:30 UTC

Winsten

Aristocrat Interim Dividend 44 Australian Cents/Share

13 mei 2025, 22:30 UTC

Winsten

Aristocrat 1H Statutory Net Profit from Continuing Operations A$511 Mln, Down 21.6%

13 mei 2025, 22:29 UTC

Winsten

Aristocrat 1H Normalized Operating Revenue A$3 Bln, Up 8.7%

13 mei 2025, 22:28 UTC

Winsten

Aristocrat 1H Normalized Net Profit A$733 Mln, Up 5.6%

13 mei 2025, 21:15 UTC

Winsten

Nu Holdings 1Q Rev $3.2B >NU

13 mei 2025, 21:03 UTC

Top Nieuws

GOP Mega Bill's Details Are Out. Now the Fighting Begins. -- WSJ

13 mei 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

13 mei 2025, 20:32 UTC

Winsten

Alcon Raises 2025 View To Sales $10.4B-$10.5B >ALC.EB

13 mei 2025, 20:31 UTC

Winsten

Alcon 1Q Sales $2.45B >ALC.EB

13 mei 2025, 20:30 UTC

Winsten

Alcon 1Q Rev $2.47B >ALC.EB

13 mei 2025, 20:30 UTC

Winsten

Alcon 1Q EPS 70c >ALC.EB

Peer Vergelijking

Prijswijziging

Roivant Sciences Ltd Prognose

Koersdoel

By TipRanks

63.79% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 18 USD  63.79%

Hoogste 18 USD

Laagste 18 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Roivant Sciences Ltd - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

5 ratings

5

Buy

0

Hold

0

Sell

Technische score

By Trading Central

11 / 11.18Steun & Weerstand

Korte Termijn

Weak Bullish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

209 / 382 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Roivant Sciences Ltd

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.